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Abstract
Background: Platelets play a central role in the pathogenesis of acute coronary syndrome 
with various clinical manifestations of unstable angina pectoris, myocardial infarction with ST 
segment elevation, and myocardial infarction without ST segment elevation. Mean platelet 
volume (MPV), the average size of platelets in blood obtained from routine blood tests, reflects 
the activation of platelets. Previous study revealed that higher MPV showed a higher thrombotic 
potential, by increasing the platelet activation, secretion of tromboxan A2 and the expression 
of glycoprotein Ib and IIb/IIIa receptors. This study aims to determine whether the MPV may 
predict the major cardiovascular events in patients with acute coronary syndrome.
Metode: We perform a retrospective cohort study involving 372 patients with acute coroanry 
syndrome who admitted to Intensive Cardiac Care Unit Dr. Sardjito Hospital Yogyakarta. The 
research is conducted between January 2009 to January 2011, comprising 180 (48.3%) STEMI 
patients, 87 (23.3%)NSTEMI patients and 105 (28.4%) unastable angina patients. Subjects 
are further grouped as those with high MPV and low MPV. MPV measurement is obtained on 
routine blood tests of those patients.The major adverse cardiovascular events are cardiovascular 
death, non fatal reinfarction, stroke, acute heart failure and cardiogenic shock.
Result: Cut-off value of MPV in this study is 8.85 fL determined with ROC curve analysis. The 
major adverse cardiovascular events is significantly higher in those with MPV >8.85 fL compared 
with those with the MPV ≤8.85 fL (incidence: 28.4% vs. 18.9%, p = 0.034), with the relative risk 
(RR) 1.65, 95% CI 1.037-2.783. The mean MPV in patients with major adverse cardiovascular 
events was significantly higher as compared to those without major adverse cardiovascular 
events (9.506 ± 1.76 fl vs.8.96 ± 1.45 fl, p = 0.001). 
Conclusion: Mean platelet volume (MPV) are associated with major adverse cardiovascular 
events in acute coronary syndrome. The high MPV may be considered as a predictor of major 
cardiovascular events in patients with acute coronary syndrome.
Keywords: acute coronary syndrome, mean platelet volume, major adverse cardiovascular 
events.
It has been known that platelet has a 
central role in initiation and propagation of 
acute coronary syndrome. It starts with platelet 
activation and followed by platelet-endothel 
adhesion, platelet aggregation, coagulation 
cascade activation and platelet-fibrin plug 
formation. The formation will reduce or block 
coronary artery lumen and potentially cause 
microinfarction and macroinfarction of distal 
myocardia.2
Platelet is a blood element which is 
heterogenous in its size, shape, density and 
reactivity. The changes in these parameters 
Introduction
Coronary heart disease as an underlying 
cause of ischemic heart disease can be manifested 
as asymptomatic, stable angina pectoris, and 
acute coronary syndrome. The spectrum of acute 
coronary syndrome can be unstable angina, ST-
elevation acute myocardial infarction (STEMI) 
and non STEMI. The pathogenesis of acute 
coronary syndrome is erosion, fissure or ruptur of 
unstable atherosclerotic plaque, which is followed 
by platelet activation and trombus formation in 
various degree of severity. Eventually, this event 
can be clinically manifested shortly.1
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associate with clinical manifestation of acute 
coronary syndrome as a precipitating and 
propagation factor. Mean platelet volume (MPV) 
is average platelet size in circulation and becomes 
one important biological variable. Large platelet 
has higher thrombotic potency as compared with 
the small ones. Large platelet has higher density, 
faster collagen aggregation, higher thromboxan 
A2 concentration and increased glicoprotein Ib 
and IIb/IIIa receptor expression.3
This research is performed to investigate 
whether high MPV as a biomarker of platelet 
activation in patients with acute coronary syndrome 
in early phase of admission is beneficial to predict 
the worsening clinical condition of patients under 
acute treatment of acute coronary syndrome. The 
worsening clinical condition includes major adverse 
cardiovascular events, i.e. cardiovascular death, 
reinfarction, stroke, acute pulmonary edema and 
cardiogenic shock. 
Currently, several markers both clinical or 
laboratory markers have been developed as a risk 
predictor in acute coronary syndrome. However, 
not a single measurement consistently shows a 
powerful predictor of clinical worsening of acute 
coronary syndrome. An MPV value, routinely 
measured in blood count measurement in all 
patients hospitalised for acute coronary syndrome, 
can be used as a marker for clinical worsening 
during intensive hospitalisaton for acute coronary 
syndrome.   
Methods
Design and Subject
The design of this research is a retrospective 
cohort study. The research is performed in Dr. 
Sardjito Hospital, Yogyakarta, Indonesia. The 
subject of this study is patients with acute 
coronary syndrome undergoing intensive 
hospitalisation in ICCU of Dr. Sardjito Hospital, 
Yogyakarta, Indonesia between January 2009 
and January 2011. 
The inclusion criteria for subject enrollment 
are (1) patients with acute coronary syndrome which 
consist of those diagnose as STEMI, nonSTEMI 
and unstable angina, (2) male and female with age 
between 30 and 75 years old, (3) the data of MPV is 
accessible in medical record. The exclusion criteria 
are (1) the presence of clinical, laboratory and/or 
rontgenology evidence of chronic kidney disease 
need renal replacement therapy, severe congestive 
heart failure NYHA class III/IV, hepatic cirrhosis, 
severe infection or sepsis, chronic inflammation 
disease, thromboemboli disease and malignancy, 
(2) pregnancy and (3) incomplete variable data 
for analysis. 
Measurement 
The research is performed by examining 
medical records of the subjects. The medical 
records are containing patients with acute 
coronary syndrome hospitalised between 
January 2009 and December 2010. The data of 
the subjects were collected and recorded, i.e. 
years of age, gender, chest pain onset, history 
of disease of hypertension, diabetes mellitus, 
smoking, chronic inflammation disease, chronic 
kidney disease, 12-lead electrocardiogram, 
Killip class measurement, the interpretation of 
chest X ray and laboratory data. The laboratory 
data is hematology (leukocyte count, platelet 
count, MPV and platelet distribution width), 
biochemistry (liver function, renal function, 
glucose), electrolite, cardiac enzyme (CK-MB 
and troponin I) and lipid profile. 
An MPV is measured from average size of 
platelets in circulation, readily available in routine 
hematology examination. The measurement of 
MPV is performed in the early hospital admission. 
Based on this MPV value, subjects are divided 
into two groups, i.e. group with high MPV and 
group with low MPV. 
The clinical outcome is major adverse 
cardiovascular event during ICCU hospitalisation 
which consist of cardiovascular death, non 
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fatal reinfarction, stroke, acute heart failure 
and cardiogenic shock. Cardiovascular death 
is cardiac cause mortality such as profound 
cardiogenic shock, fatal arrhytmia or sudden 
death. Acute heart failure is indicated with 
the presence of acute pulmonary edema. 
Cardiogenic shock is determined by the presence 
of reduced systolic blood pressure (< 90 mmHg) 
and utilisation of inotropic/vasopressor drugs. 
Reinfarction is indicated by the presence of 
recurrent angina, ST segment elevation and 
increased cardiac enzyme during hospitalisation. 
The data of clinical outcome is recorded in the 
medical record. 
Statistics Analysis
The baseline characteristics is presented 
in mean and standard deviation or median and 
interquartile range for continuous data. To compare 
the mean/median difference between two groups, 
Student T test or Mann Whitney U test is utilised. 
The cathegorical data is presented in proportion 
(percentage). To compare the proportion difference 
betwen two groups, the Chi square or Fisher exact 
test is utilised. Multivariable logistic regression 
analysis is performed to analyse several predictor 
variables. To determine the cut off value of MPV 
and allocate the groups, an ROC curve analysis 
is performed. 
Result
From medical record, there are 372 
subjects suitable the inclusion and exclusion 
criteria. They consist of 180 (48.3 %) subjects 
with STEMI, 87 (23.3 %) subjects with NSTEMI 
and 105 (28.4 %) subjects with unstable angina. 
The mean±standard deviation  value of MPV in 
all subjects is 9.09±1.35 fL, with minimum value 
5.5 fL and maximum value 13.4 fL. 
To determine the impact of MPV on major 
adverse cardiovascular events, subjects are 
divided into two groups based on the cut off 
value. To determine the best cut off value,  an 
ROC curve is constructed. The are under the 
curve of MPV is 0.598 , 95% CI 0.527 – 0.669. 
The cut off value is choosen for maximal 
sensitivity and specificity and the result is 8.85 
fL with sensitivity 61.8 % and specificity 58.2 %. 
Figure 1 shows the result of ROC curve.
Based on the MPV value of 8.85 fL, subjects 
are divided into group with high MPV (MPV > 8.85 
fL) and group with low MPV (MPV ≤ 8.85 fL). 
Table 1 shows several variables that may 
influence the MPV value such as age, gender, 
haemoglobin level, leukocyte count, platelet count, 
systolic and diastolic blood pressure, diabetes 
mellitus, hypertension, smoking, dyslipidemia 
and blood glucose level.  The variable that is 
significantly different is systolic blood pressure with 
mean value 125.6±26.0 mmHg versus 133.4±30.1 
mmHg in subjects with high MPV as compared to 
subjects with low MPV.  The risk factor for coronary 
heart disease, i.e. diabetes mellitus and smoking is 
greater in subjects with high MPV as compared to 
those with low MPV. In contrast, the proportion of 
hypertension and dyslipidemia is higher in subjects 
with low MPV.  Glucose level is higher in subjects 
with high MPV if compared with subjects with low 
MPV, the value is 175.8±102.4 g/dL compared with 
Figure 1. The ROC curve of MPV value in 
association with major adverse cardiovascular 
events. Area under the ROC curve is 0.598, 95% 
CI 0.527-0.669.
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163.0±82.8 g/dL, the p > 0.05. 
The  inc idence  o f  ma jo r  adverse 
cardiovascular events during intensive 
hospitalisation in acute coronary syndrome is 
influenced by several factors. Platelet activation 
is one of factors that influence the adverse 
events. In this research, we analyse the value of 
MPV, which is a parameter of platelet activation, 
as a factor that may affect the incidence of 
major adverse cardiovascular events. The major 
adverse cardiovascular events in this research 
is  cardiovascular death, reinfarction, stroke, 
cardiogenic shock and acute heart failure. 
The role of the MPV value on major adverse 
cardiovascular events  in 372 subjects with acute 
coronary syndrome which is allocated into two 
groups is presented in table 2. It shows that 
the major adverse cardiovascular event occurs 
in 90 (24.2 %) of 372 subjects. The proportion 
of MACE in the subjects with high MPV is 
significantly higher as compared to subjects with 
low MPV (26.4 % versus 16.9 % respectively, the 
p value of difference is 0.024). 
Table 3 indicates that the proportion of 
major adverse cardiovascular events in subjects 
hospitalised with acute coronary syndrome in 
those with high MPV is 1.65 higher as compared 
with subjects with low MPV. The 95% confidence 
interval  is 1.027 – 2.762 and the significance 
with p value = 0.024. 
In table 1, it is shown that systolic blood 
pressure is the only variable that is significantly 
higher in subjects with high MPV as compared to 
subjects with low MPV. It indicates that systolic 
blood pressure may be a confounding factor 
taht influence the incidence of major adverse 
cardiovascular events. The regression analysis 
of this variable is shown in table 4. 
The incidence of cardiovascular death in 
this research is 8.3 %, i.e. 31 out of 372 subjects. 
The incidence of death in subjects with high MPV 
is 10.6 % and in subjects with low MPV is 5.5 %. 
Table 2. The 2x2 table showing the relation between MPV and major adverse cardiovascular event 
in patients with acute coronary syndrome 
With major adverse 
cardiovascular events
n = 90




n = 372 p value
High MPV (> 8.85 fL) 59 (28.4 %) 149 (71.6 %) 208 0.034
Low MPV (≤ 8.85 fL) 31 (18.9 %) 133 (81.1 %) 164
Total 90 282 372
Table 1. The baseline characteristics data of the research subjects
Baseline Characteristics
High MPV
(MPV > 8.85 fL)
n = 208
Low MPV
(MPV ≤ 8.85 fL)
n = 164
p value
Male gender 157 (75.5 %) 118 (72 %) 0.441
Diabetes mellitus 65 (31.3 %) 37 (22.6 %) 0.062
Hypertension 115 (55.3 %) 98 (59.8 %) 0.387
Smoking 118 (56.7 %) 78 (47.6 %) 0.079
Dyslipidemia 121 (58.2 %) 99 (60.4 %) 0.430
Age 58.7±11.24 59.2±11.9 0.716
Systolic blood pressure 125.6±26.0 133.4±30.1 0.009
Diastolic blood pressure 75.5±17.3 78.2±15.9 0.132
Hemoglobin 13.84±1.83 13.69±1.87 0.464
Leukocyte count 11.67±4.59 11.71±4.96 0.941
Platelet 249.2±82.8 241.6±65.0 0.345
Glucose 175.8±102.4 163.0±82.8 0.238
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(≤ 8.85 fL) RR (95% CI) p value
Major Adverse Cardiovascular Events (%) 59 (28.4 %) 31 (18.9 %) 1.65 (1.037-2.783) 0.034
RR is relative risk
The significance p value is 0.076. The odd ratio for 
death is 2.027, 95% confidence interval is 0.911 
– 4.55. Although the result shows no statistical 
significance, clinical significance shows that 
high MPV value has valuable role on predicting 
cardiovascular death twice as compared with 
subjects with low MPV (shown in table 5). Acute 
heart failure (acute pulmonary edema) occurs in 
50 subjects (13.4 %). In subjects with high MPV 
the proportion of acute heart failure is 15.9 % and 
subjects with low MPV the proportion is 10.4 %. 
The p value for difference is 0.123. Although the 
statistical significance is not reached, the clinical 
significance is important because the odd ration 
is 1.631 (95 % confidence interval 0.631-3.046) 
(shown in table 5). 
In the subset of subjects with acute 
myocardial infarction, both with STEMI and 
NSTEMI, the major adverse cardiovascular 
events occurs in 79 (29.6 %) out of 267 subjects 
with acute myocardial infarction. In subjects 
with high MPV, the proportion of major adverse 
cardiovascular events is higher as compared 
with subjects with low MPV, i.e. 33.85 % versus 
23.9 % with p value for significance 0.061. The 
proportion of death during hospitalisation is 10.5 
% in subjects with acute myocardial infarction. In 
subjects with high MPV the proportion of death 
is 13 % whereas in subjects with low MPV the 
proportion of death is 7.1 %, the p value for 
significance is 0.120. The incidence of acute 
pulmonary edema (acute heart failure) is also 
higher is subjects with high MPV as compared 
with subjects with low MPV, i.e. 16.2 % versus 
12.4 % with p value for significance 0.199 (shown 
in table 6). 
The  inc idence  o f  ma jo r  adverse 
cardiovascular events, cardiovascular death 
and acute pulmonary edema indicates higher in 
subjects with high MPV as compared to those 
with low MPV in the subset of patients with 
acute myocardial infarction. Although statistically 
not significance, clinical significance may be 
important especially in the incidence of death 
since it has twice risk in subjects with high MPVas 
compared to subjects with low MPV. 
According to the pathophysiology of 
thrombosis, in subjects with STEMI the thrombosis 
is more severe as compared to nonSTEMI and 
unstable angina. The subanalysis in subjects 
with STEMI ( n = 180 subjects) indicated that the 
incidence of major adverse cardiovascular events 
is 30.6 % (55 out of 180 subjects), death is 9.4 
% (17 out of 180 subjects) and acute pulmonary 
edema is 17.2 % (31 out of 180 subjects). In 
subjects with high MPV, the incidence of major 
adverse cardiovascular events , cardiovascular 
death and acute pulmonary edema is higher 
Table 4. Multivariable regression analysis of factors that influence the relation between MPV and 
major adverse cardiovascular events
Univariate 
RR (95 % CI) p value
Multivariable
RR (95% CI) p value
High MPV (> 8.85 fL) 
versus Low MPV (≤ 8.85 fL) 
1.65 (1.037-2.782) 0.034 1.523 (0.921-2.518) 0.100
Mean systolic blood pressure 0.990 (0.981 – 0.999) 0.034
RR is relative risk 
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Table 6. The impact of high MPV on major adverse cardiovascular event, death and acute heart failure 




(≤ 8.85 fL) RR (95% CI) P value
Major adverse cardiovascular events (%) 52 (33.8 %) 27 (23.9 %) 1.62 (0.940-2.804) 0.081
Death (%) 20 (13.0 %) 8 (7.1 %) 1.96 (0.830-4.624) 0.830
Acute pumonary edema (%) 28 (18.0 %) 14 (12.4 %) 1.57 (0.785-3.144) 0.199
RR is relative risk
as compared with subjects with low MPV, i.e. 
32.7 % versus 27.54 %, p value 0.447 for major 
adverse cardiovascular events, 11.2 % versus 
6.8 %, p value 0.325 for cardiovascular death and 
17.8 % versus 16.4 %, p value 0.818 foe acute 
pulmonary edema. Although statistically not 
significance, clinically the difference is important 
especially in the incidence of major adverse 
cardiovascular events (shown in table 7). 
The mean value of MPV in subjects 
with major adverse cardiovascular events is 
significantly higher as compared to subjects 
without major adverse cardiovascular events, 
i.e. 9.506±1.76 fL versus 8.96±1.45 fL with 
the significance p value 0.001. It indicates that 
mean value of MPV is significantly higher in 
subjects with high MPV. The mean value of 
MPV in subjects suffering from cardiovascular 
death is significantly higher as compared with 
subjects who survive, i.e. 9.945±1.77 fL versus 
9.010±1.500 with the significance p value 
0.003. The mean value of MPV in subjects with 
acute pulmonary edema is higher as compared 
to subjects without acute pulmonary edema, 
i.e. 9.48±1.61 fL versus 9.03±1.49 fL with the 
significance p value 0.055. 
Discussion
Mean platelet volume (MPV) is a marker 
of platelet size, function and activation including 
aggregation, release of thromboxan A2 , platelet 
factor 4 and beta-thrombomodulin, expression of 
glicoprotein Ib and glicoprotein IIb/IIIa receptors.5 
Larger platelet has more active metabolism 
and eznyme  system and more production of 
thromboxan A2 as compared to smaller platelet. 
The MPV  value has negative correlation with 
platelet count in patients with peripheral artery 
disease and healthy individual.6
Platelet activation occurs just before the 
episode of acute coronary syndrome.  The need 
of platelet is increasing in the site of coronary 
atherosclerosis plaque which cause larger 
platelet being release from bone marrow. In 
the observation, increased platelet volume can 
persist during hospital treatment in patients with 
acute coronary syndrome.  It indicates that MPV 
is an early indicator of prolonged disturbance and 
a marker to longterm outcome.7
The normal value of MPV is 7.5 – 11.5 fL. 
The cut off value of MPV to discriminate between 
large and small in several studies is varied. In 
the subjects with acute myocardial infarction, 2 
Table 5. The impact of high MPV on major adverse cardiovascular event, death and acute heart failure 




(≤ 8.85 fL) RR (95% CI) P value
Major adverse cardiovascular events (%) 59 (28.4 %) 21 (18.9 %) 1.65 (1.027-2.783) 0.034
Death (%) 22 (10.65 %) 9 (5.5 %) 2.04 (0.911-4.553) 0.078
Acute pumonary edema (%) 33 (15.9 %) 17 (10.4 %) 1.63 (0.831-3.046) 0.123
RR is relative risk
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Table 7. The impact of high MPV on major adverse cardiovascular event, death and acute heart failure 




(≤ 8.85 fL) RR (95% CI) P value
Major adverse cardiovascular events (%) 35 (32.7 %) 20 (27.4 %) 1.29 (0.670-2.477) 0.447
Death (%) 12 (11.2 %) 5 (6.8 %) 1.72 (0.578-5.103) 0.325
Acute pumonary edema (%) 19 (17.8 %) 12 (16.4 %) 1.09 (0.497-2.426) 0.818
RR is relative risk
studies use the cut off value of ≥ 10.3 fL 5,8 and 1 
study use the cut off value 9 fL.9 The ROC curve 
analysis in this research yields the cut off value of 
MPV 8.85 fL which has sensitivity of 61.8 % and 
specificity of 58.2 %. In several studies, mean 
MPV in the same population show different value. 
In this research mean value of MPV in acute 
coronary syndrome is 9.09±1.35 fL with minimal 
value of 5.5 fL and maximal value of 13.4 fL. The 
multicenter study involving 3134 patients with 
cerebrovascular disease and risk of stroke, the 
mean value of MPV is different in every regions, 
with the all mean value of 10.0 fL.10
The MPV in subjects with risk factor of 
cardiovascular disease shows that in prehypertensive 
patients, the MPV value is significantly higher as 
compared to normal subjects. The MPV has 
positive correlation with systolic blood pressure, 
body mass index and insulin resistance in subjects 
with prehypertension.11 In this research, there is 
a significant different in systolic blood pressure 
in which the higher systolic blood pressure in 
subjects with lower MPV. The blood glucose 
level is significantly higher in subjects with higher 
MPV as compared to those with low MPV. This 
contradictory result needs to be corroborated. The 
MPV is increased in condition with cardiovascular 
risk factore such as hyperkholesterolemia, diabetes 
mellitus but not in essential hypertension. In acute 
myocardial infarction, acute ischemic stroke, 
preeklampsia and renalis artery stenosis, the MPV 
value is increasing.12
The study by Yilmaz et al. (2008) that 
differentiate the MPV value in subjects with 
nonSTEMI,unstable angina and stabil coronary 
artery disease, yield the result as follows 
: 10.4±0.6 fL, 10.0±0.7 fL and 8.9±0.7 fL 
respectively and significantly different.3 Other 
study shows similar result, i.e. the highest MPV 
value is found in acute myocardia infarction, and 
then in unstable angina pectoris and the least is 
found in stabil coronary heart disease.7 In this 
study, the mean value of MVP is 9.18±1.55 fL in 
STEMI, 9.14±1.6 fL in NSTEMI and 8.89±1.47 
fL in unstable angina. Furthermore the higher 
mean value of MVP is found in subset of acute 
myocardial infarction than in unstable angina 
pectoris.
The current meta analyses for MPV as a 
predictor of cardiovascular risk involve 16 cross 
sectional studies in acute myocardial infarction, 
3 cohort studies in acute myocardial infarction 
and 5 cohort studies in post angioplasty patients. 
The cross sectional studies show that acute 
myocardial infarction has higher MPV value as 
compared with non acute myocardial infarction. 
Non acute myocardial infarction consists of 
unstable angina pectoris, stable coronary 
heart disease and non coronary heart disease 
patients.13 
The  inc idence  o f  ma jo r  adverse 
cardiovascular event in this study is 24.2 %. 
The incidence of major adverse cardiovascular 
event is significantly higher in patients with 
higher MPV as compared with patients with 
lower MPV. The relative risk to develop major 
adverse cardiovascular event is 1.65 time in 
partients with higher MPV. It indicates that high 
MPV is a predictor for the development of major 
adverse cardiovascular events in acute coronary 
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syndrome patients. Previous study supported 
the result of our study by showing the positive 
association between admission MPV value with 
major adverse cardiovascular events during 
hospitalisation. 5 
In other study, it was shown that MPV is an 
independent risk factor for recurrent ischemia and 
death.13 The association between MPV 6 month 
post myocardial infarction in male patients is 
associated with mortality within 2 years follow up. 
The high MPV value associates with independent 
risk factor for recurrent infarct and cardiovascular 
mortality.14 In patients with a history of stroke, 
high MPV value is a independent predictor for 
recurrent stroke.12 The increasing MPV in acute 
myocardial infarction associates with the extent 
of infarction and increase risk to develop left 
ventricular dysfunction and mural thrombus.2 
Elevated MPV is an independent risk factor 
for acute heart failure in patients with acute 
myocardial infarction. 9 The impact of MPV value 
on the incidence of acute pulmonary edema 
in this research is higher in subjects with high 
MPV as compared to those with low MPV. The 
odd ratio of high MPV value to develop heart 
failure is 1.631, however there is no statistically 
significant. Previous study indicates that platelet 
indices, i.e. MPV, PDW and platelet large cell 
ratio independently associated with infarct/
ischemia type (transmural or subendocardial), 
infarct location (anterior, lateral, posterior or other 
wall location), infarct consequence as measured 
with Killip class, time before treatment, ischemic 
episode and the extent of occluded coronary 
vessels.7 
Increased MPV value associated with 
worse clinical outcome and disturbance in 
reperfusion in patients with acute myocardial 
infarction. Relative and absolute neutrophil 
count and elevated MPV value on admission 
associated independently with microvascular 
perfusion disturbance in patients undergoing 
primary percutaneous coronary intervention. The 
combined markers are indication of worsened 
microvascular injury in patients with acute 
myocardial infarction.15 In patients with STEMI, 
MPV value may have implication in treatment 
strategy.5 Only patients with increased MPV 
response well with abciximab. Therefore, by 
measuring MPV value, the efficacy of glycoprotein 
IIb/IIIa inhibitor and other antiplatelets can be 
determined. 13 The incidence of major adverse 
cardiovascular events is higher in subjects with 
high MPV value as compared to subjects with 
low MPV value. The incidence of death and 
acute pulmonary edema is also higher in subjects 
with high MPV value. Although statistically 
not significant, the clinical value may be of 
significant. 
Conclusion
The high MPV (> 8.85 fL) has higher 
incidence of major adverse cardiovascular event 
in patients with acute coronary syndrome as 
compared with patients with lower MPV (≤ 8.85 
fL), this difference is statistically significant (p < 
0.05). The high MPV is a significant predictor 
for major adverse cardiovascular event in acute 
coronary syndrome with relative risk 1.65.  
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